Biomarkers of radiation‐induced vascular injury

Venkatesulu, Bhanu Prasad; Sanders, Kevin E.; Hsieh, Cheng‐En; Kim, Byung Kyu; Krishnan, Sunil

doi:10.1002/cnr2.1152

Cited by 8 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first question requires a thorough work-up of the endothelial toxicity of agents commonly used in the pre-SCT setting, such as fludarabine, alkylators, and anthracyclines, but also irradiation [ 91 , 92 ], but of course also of the contributions of vascular comorbidity unrelated to the neoplastic disease. Regarding the second question, a large variety of drugs frequently employed during or after SCT, such as CNI, sirolimus, calcium channel blockers, and angiotensin-II inhibitors can affect endothelial integrity and may demand patient-based endothelial monitoring [ 93 – 96 ].…”

Section: Adjusting Anti-neoplastic and Immunosuppressive Regimens To Endothelial Cell Functionmentioning

confidence: 99%

Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation

Luft

Dreger

Radujkovic

2021

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (alloSCT) carries the promise of cure for many malignant and non-malignant diseases of the lympho-hematopoietic system. Although outcome has improved considerably since the pioneering Seattle achievements more than 5 decades ago, non-relapse mortality (NRM) remains a major burden of alloSCT. There is increasing evidence that endothelial dysfunction is involved in many of the life-threatening complications of alloSCT, such as sinusoidal obstruction syndrome/venoocclusive disease, transplant-associated thrombotic microangiopathy, and refractory acute graft-versus host disease. This review delineates the role of the endothelium in severe complications after alloSCT and describes the current status of search for biomarkers predicting endothelial complications, including markers of endothelial vulnerability and markers of endothelial injury. Finally, implications of our current understanding of transplant-associated endothelial pathology for prevention and management of complications after alloSCT are discussed.

show abstract

Section: Adjusting Anti-neoplastic and Immunosuppressive Regimens To Endothelial Cell Functionmentioning

confidence: 99%

Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation

Luft

Dreger

Radujkovic

2021

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Neoadjuvant chemoradiotherapy in esophageal carcinoma may result in a complete response (25% of patients), partial response (55%), or no response (20%) [ 113 , 114 ]. The use of pre-treatment imaging in radiomics [ 115 , 116 ] and patient-derived plasma samples is beginning to be used in the search for radiation biomarkers [ 117 ] to predict treatment response. However, patient-derived organoid models in development of predictive biomarkers or screening of radio-modulators can be a very useful tool.…”

Section: Ex Vivo Models In Radiotherapymentioning

confidence: 99%

Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy

Zitter

Chugh

Saha

2022

Cancers

View full text Add to dashboard Cite

The field of cancer research is famous for its incremental steps in improving therapy. The consistent but slow rate of improvement is greatly due to its meticulous use of consistent cancer biology models. However, as we enter an era of increasingly personalized cancer care, including chemo and radiotherapy, our cancer models must be equally able to be applied to all individuals. Patient-derived organoid (PDO) and organ-in-chip (OIC) models based on the micro-physiological bioengineered platform have already been considered key components for preclinical and translational studies. Accounting for patient variability is one of the greatest challenges in the crossover from preclinical development to clinical trials and patient derived organoids may offer a steppingstone between the two. In this review, we highlight how incorporating PDO’s and OIC’s into the development of cancer therapy promises to increase the efficiency of our therapeutics.

show abstract

“…Radiation-induced vascular injury is commonly observed in cancer patients after radiation therapy ( Murphy et al, 2012 ; Venkatesulu et al, 2019 ; Ramadan et al, 2021 ). The major drivers of radiation-induced vascular injury are oxidative stress, DNA damage, and inflammation ( Lafargue et al, 2017 ; Baselet et al, 2019 ).…”

Section: Cellular Senescence Of Endothelial Cellsmentioning

confidence: 99%

Vascular Endothelial Senescence: Pathobiological Insights, Emerging Long Noncoding RNA Targets, Challenges and Therapeutic Opportunities

Sun

Feinberg

2021

Front. Physiol.

View full text Add to dashboard Cite

Cellular senescence is a stable form of cell cycle arrest in response to various stressors. While it serves as an endogenous pro-resolving mechanism, detrimental effects ensue when it is dysregulated. In this review, we introduce recent advances for cellular senescence and inflammaging, the underlying mechanisms for the reduction of nicotinamide adenine dinucleotide in tissues during aging, new knowledge learned from p16 reporter mice, and the development of machine learning algorithms in cellular senescence. We focus on pathobiological insights underlying cellular senescence of the vascular endothelium, a critical interface between blood and all tissues. Common causes and hallmarks of endothelial senescence are highlighted as well as recent advances in endothelial senescence. The regulation of cellular senescence involves multiple mechanistic layers involving chromatin, DNA, RNA, and protein levels. New targets are discussed including the roles of long noncoding RNAs in regulating endothelial cellular senescence. Emerging small molecules are highlighted that have anti-aging or anti-senescence effects in age-related diseases and impact homeostatic control of the vascular endothelium. Lastly, challenges and future directions are discussed including heterogeneity of endothelial cells and endothelial senescence, senescent markers and detection of senescent endothelial cells, evolutionary differences for immune surveillance in mice and humans, and long noncoding RNAs as therapeutic targets in attenuating cellular senescence. Accumulating studies indicate that cellular senescence is reversible. A better understanding of endothelial cellular senescence through lifestyle and pharmacological interventions holds promise to foster a new frontier in the management of cardiovascular disease risk.

show abstract

Biomarkers of radiation‐induced vascular injury

Cited by 8 publications

References 54 publications

Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation

Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation

Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy

Vascular Endothelial Senescence: Pathobiological Insights, Emerging Long Noncoding RNA Targets, Challenges and Therapeutic Opportunities

Contact Info

Product

Resources

About